Ignite Creation Date:
2024-07-17 @ 11:14 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06472037
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-06-24
First Post:
2024-06-18
Brief Title:
The Efficacy of Gemcitabine and Nab-palitaxe Combined With Cadonilimab Sequential Short-course Radiotherapy in the Treatment of Patients With Locally Advanced Pancreatic Ductal Adenocarcinoma
Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Organization:
Tianjin Medical University Cancer Institute and Hospital
Study Overview
Official Title:
A Prospective Single-arm Exploratory Phase II Clinical Study Evaluating the Efficacy of Gemcitabine and Nab-palitaxe Combined With Cadonilimab Sequential Short-course Radiotherapy in the Treatment of Patients With Locally Advanced Pancreatic Ductal Adenocarcinoma
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A prospective single-arm exploratory phase II clinical study evaluating the efficacy of Gemcitabine and Nab-palitaxe combined with Cadonilimab sequential short-course radiotherapy in the treatment of patients with locally advanced pancreatic ductal adenocarcinoma
Detailed Description:
This trial is a prospective single-arm single-center phase II clinical study aimed at investigating the efficacy and safety of Cadonilimab combined with Gemcitabine and Nab-palitaxe in short-course radiotherapy neoadjuvant treatment for locally advanced pancreatic ductal adenocarcinoma patients Patients will receive Gemcitabine and Nab-palitaxe combined with Cadonilimab treatment for one cycle followed by sequential short-course radiotherapy and then Gemcitabine and Nab-palitaxe combined with Cadonilimab treatment If feasible radical surgery will be performed to assess efficacy A total of 8 cycles of chemotherapy will be administered followed by Cadonilimab maintenance for up to 1 year
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None